Supplemental Table 1-3 from SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells

Supplemental Table 1. Summary of patient characteristics with newly diagnosed HNSCC. Supplemental Table 2. Summary of patient characteristics with recurrent and/or metastatic HNSCC. Supplemental Table 3. Injection of FaDu-SMAD4 cells results in lower take rate in mice compared to the control cell line and shows no signs of metastatic lesion.